Clinical efficacy of membrane-free stem cell extracts for the treatment of canine atopic dermatitis

Kim YS, Ha SE, Bae H, Lee D, Yu DH, Kim GS (2022): Clinical efficacy of membrane-free stem cell extracts for the treatment of canine atopic dermatitis. Vet Med-Czech 67, 463–470.

download PDF

Despite various treatment options for canine atopic dermatitis (cAD), therapeutic limitations still exist, including adverse effects and low absorption ratios. This study evaluated the effects of a membrane-free stem cell extract (MFSCE) on the clinical signs of atopic dogs. Thirty client-owned dogs previously diagnosed with cAD were separated into placebo (n = 10) and MFSCE-treated groups (n = 20). The dogs were treated with a cream (MFSCE and placebo) via dermal administration twice daily for 14 days, and the clinical response was recorded on days 0, 7, and 14. The MFSCE-treated group showed significantly decreased severity of pruritus on day 14 compared to that on day 0. In addition, the erythema, pigmentation, skin dryness, and thickness were remarkably decreased in the MFSCE-treated group on day 14 compared to those on day 0 whereas no significant changes were observed in the placebo-treated group. No general clinical signs or adverse effects were observed in this study. These results suggest that MFSCE could be a surrogate treatment option for cAD.

Behrend EN, Kemppainen RJ. Glucocorticoid therapy. Pharmacology, indications, and complications. Vet Clin North Am Small Anim Pract. 1997 Mar;27(2):187-213.
Cosgrove SB, Wren JA, Cleaver DM, Walsh KF, Follis SI, King VI, Tena JK, Stegemann MR. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013 Dec;24(6):587-97.
Daltro SRT, Meira CS, Santos IP, Ribeiro Dos Santos R, Soares MBP. Mesenchymal stem cells and atopic dermatitis: A review. Front Cell Dev Biol. 2020 May 14;8:326.
de Oliveira Ramos F, Malard PF, Brunel HDSS, Paludo GR, de Castro MB, da Silva PHS, da Cunha Barreto-Vianna AR. Canine atopic dermatitis attenuated by mesenchymal stem cells. J Adv Vet Anim Res. 2020 Sep 1;7(3):554-65.
De Souza A, Strober BE. Principles of topical therapy. In: Fitzpatrick TB, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 6th ed. New York: McGraw-Hill; 2008. p. 2643-51.
El Hachem M, Di Mauro G, Rotunno R, Giancristoforo S, De Ranieri C, Carlevaris CM, Verga MC, Dello Iacono I. Pruritus in pediatric patients with atopic dermatitis: A multidisciplinary approach – Summary document from an Italian expert group. Ital J Pediatr. 2020 Jan 30;46(1):11.
Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician. 2009 Jan 15;79(2):135-40.
Forsythe P, Paterson S. Ciclosporin 10 years on: Indications and efficacy. Vet Rec. 2014 Mar;174(Suppl_2):13-21.
Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, Mitton-Fry M. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014 Aug;37(4):317-24.
Ha SE, Vetrivel P, Kim SM, Bhosale PB, Kim HH, Pak JE, Heo JD, Kim YS, Kim GS. Inhibitory effect of membrane free stem cell components derived from adipose tissues on skin inflammation in keratinocytes. Mol Med Rep. 2022 Apr;25(4):125.
Hillier A, Lloyd DH, Weese JS, Blondeau JM, Boothe D, Breitschwerdt E, Guardabassi L, Papich MG, Rankin S, Turnidge JD, Sykes JE. Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases). Vet Dermatol. 2014 Jun;25(3):163-e43.
Jee MK, Im YB, Choi JI, Kang SK. Compensation of cATSCs-derived TGFβ1 and IL10 expressions was effectively modulated atopic dermatitis. Cell Death Dis. 2013 Feb 14;4(2):e497.
Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006 May;24(5):1294-301.
Kim HJ, Park JS. Usage of human mesenchymal stem cells in cell-based therapy: Advantages and disadvantages. Dev Reprod. 2017 Mar;21(1):1-10.
Kong JS, Park JH, Yoo SA, Kim KM, Bae YJ, Park YJ, Cho CS, Hwang D, Kim WU. Dynamic transcriptome analysis unveils key proresolving factors of chronic inflammatory arthritis. J Clin Invest. 2020 Aug 3;130(8):3974-86.
Lee HJ, Jung M, Kim JH, Yoon NY, Choi EH. The effect of adipose-derived stem cell-cultured media on oxazolone treated atopic dermatitis-like murine model. Ann Dermatol. 2012 May;24(2):181-8.
Lee HJ, Lee SM, Moon YG, Jung YS, Lee JH, Venkatarame Gowda Saralamma V, Kim YS, Pak JE, Lee HJ, Kim GS, Heo JD. Membrane-free stem cell components inhibit interleukin-1α-stimulated inflammation and cartilage degradation in vitro and in vivo: A rat model of osteoarthritis. Int J Mol Sci. 2019 Sep 30;20(19):4869.
Lu L, Dai C, Zhang Z, Du H, Li S, Ye P, Fu Q, Zhang L, Wu X, Dong Y, Song Y, Zhao D, Pang Y, Bao C. Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: A prospective, randomized, double-blind, active-controlled, phase IIb clinical trial. Stem Cell Res Ther. 2019 May 21;10(1):143.
Marks PW, Witten CM, Califf RM. Clarifying stem-cell therapy’s benefits and risks. N Engl J Med. 2017 Mar 16;376(11):1007-9.
Marsella R. Atopic dermatitis in domestic animals: What our current understanding is and how this applies to clinical practice. Vet Sci. 2021 Jul 2;8(7):124.
Nuttall T. Topical therapy in canine atopic dermatitis: New products. Companion Anim. 2020 Mar;25(2):76-82.
Olivry T, Saridomichelakis M, Nuttall T, Bensignor E, Griffin CE, Hill PB; International Committe on Allergic Diseases of Animals (ICADA). Validation of the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4, a simplified severity scale for assessing skin lesions of atopic dermatitis in dogs. Vet Dermatol. 2014 Apr;25(2):77-85.
Park HS, Pang QQ, Kim YS, Kim JH, Cho EJ. Neuroprotective effect of membrane-free stem cell extract against amyloid beta 25-35-induced neurotoxicity in SH-SY5Y cells. Appl Sci. 2021;11(5): [12].
Purvis GSD, Solito E, Thiemermann C. Annexin-A1: Therapeutic potential in microvascular disease. Front Immunol. 2019 Apr 30;10:938.
Samochocki Z, Alifier M, Bodera P, Jeziorkowska R, Rosiak E, Jurkiewicz B, Glinska O, Glinski W, Stankiewicz W. T-regulatory cells in severe atopic dermatitis: Alterations related to cytokines and other lymphocyte subpopulations. Arch Dermatol Res. 2012 Dec;304(10):795-801.
Santoro D. Therapies in canine atopic dermatitis: An update. Vet Clin North Am Small Anim Pract. 2019 Jan;49(1):9-26.
Venkatarame Gowda Saralamma V, Vetrivel P, Kim SM, Ha SE, Lee HJ, Lee SJ, Kim YS, Pak JE, Lee HJ, Heo JD, Kim GS. Proteome profiling of membrane-free stem cell components by nano-ls/ms analysis and its anti-inflammatory activity. Evid Based Complement Alternat Med. 2019 Nov 4;2019:4683272.
Toshitani A, Ansel JC, Chan SC, Li SH, Hanifin JM. Increased interleukin 6 production by T-cells derived from patients with atopic dermatitis. J Invest Dermatol. 1993 Mar;100(3):299-304.
Villatoro AJ, Hermida-Prieto M, Fernandez V, Farinas F, Alcoholado C, Rodriguez-Garcia MI, Marinas-Pardo L, Becerra J. Allogeneic adipose-derived mesenchymal stem cell therapy in dogs with refractory atopic dermatitis: Clinical efficacy and safety. Vet Rec. 2018 Dec 1;183(21):654.
Wu S, Pang Y, He Y, Zhang X, Peng L, Guo J, Zeng J. A comprehensive review of natural products against atopic dermatitis: Flavonoids, alkaloids, terpenes, glycosides and other compounds. Biomed Pharmacother. 2021 Aug;140:111741.
download PDF

© 2022 Czech Academy of Agricultural Sciences | Prohlášení o přístupnosti